Completed NA INTERVENTIONAL 1-arm NCT04639492

Postbiotic MBS and Metformin Combination in Patients With T2DM

Evaluating the Effect and Safety of Postbiotic MBS and Metformin Combination on Gut Microbiota and Symptom in Patients With Diabetes

Sponsor: Microbio Co Ltd

Conditions Type-II Diabetes

Interventions MBS oral solution

Updated 6 times since 2020 Last updated: Jan 3, 2023 Started: Nov 2, 2020 Primary completion: Jun 30, 2022 Completion: Sep 23, 2022

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A NA clinical study on Type-II Diabetes, this trial is completed. The trial is conducted by Microbio Co Ltd and has accumulated 6 data snapshots since 2020. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed NA
Jul 2024 — Sep 2024 [monthly]

Completed NA
Feb 2023 — Jul 2024 [monthly]

Completed NA

Status: Unknown Status → Completed
Dec 2022 — Feb 2023 [monthly]

Unknown Status NA

Status: Recruiting → Unknown Status
Jan 2021 — Dec 2022 [monthly]

Recruiting NA

Status: Active Not Recruiting → Recruiting

▶ Show 1 earlier version

Dec 2020 — Jan 2021 [monthly]

Active Not Recruiting NA

First recorded

Nov 2020

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Microbio Co Ltd

Data source: Microbio Co Ltd

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Taipei, Taiwan